PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is common among cancer patients who undergo chemotherapy with platinum analogues, taxanes, vinca alkaloids, epothilone, bortezomib, and thalidomide. The purpose of this study was to investigate the evidence of using drugs affecting the central nervous system (CNS) to alleviate CIPN in cancer patients. METHODS: A systematic literature search was conducted using the CINAHL, EMBASE, and Medline databases to identify randomized controlled clinical trials (RCTs) reported in English up to 2013. We identified ten trials of CNS-acting drugs used to treat CIPN in cancer patients and reviewed efficacy and safety of CNS-acting drugs for CIPN using a standard data collection form. The risk of bias in each RCT was also assessed. RESULTS: Antidepressants were used in six studies and anticonvulsants in four studies. We found positive results for amitriptyline (topical), venlafaxine, and oxcarbazepine in one study each, but the results were not sufficient to draw definite conclusions. One trial with duloxetine showed a moderate effect (effect size, 0.513, P = .003) on CIPN pain relief. However, none of the results has yet been duplicated in an RCT with a large sample size. CONCLUSIONS: Insufficient RCTs exist to confirm the efficacy of CNS agents to reduce CIPN. This study highlighted the need for and the importance of conducting well-designed RCTs to generate evidence on CIPN symptom management. Additional RCTs are warranted to accelerate the potential use of CNS drugs for CIPN in cancer patients.
PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is common among cancerpatients who undergo chemotherapy with platinum analogues, taxanes, vinca alkaloids, epothilone, bortezomib, and thalidomide. The purpose of this study was to investigate the evidence of using drugs affecting the central nervous system (CNS) to alleviate CIPN in cancerpatients. METHODS: A systematic literature search was conducted using the CINAHL, EMBASE, and Medline databases to identify randomized controlled clinical trials (RCTs) reported in English up to 2013. We identified ten trials of CNS-acting drugs used to treat CIPN in cancerpatients and reviewed efficacy and safety of CNS-acting drugs for CIPN using a standard data collection form. The risk of bias in each RCT was also assessed. RESULTS: Antidepressants were used in six studies and anticonvulsants in four studies. We found positive results for amitriptyline (topical), venlafaxine, and oxcarbazepine in one study each, but the results were not sufficient to draw definite conclusions. One trial with duloxetine showed a moderate effect (effect size, 0.513, P = .003) on CIPN pain relief. However, none of the results has yet been duplicated in an RCT with a large sample size. CONCLUSIONS: Insufficient RCTs exist to confirm the efficacy of CNS agents to reduce CIPN. This study highlighted the need for and the importance of conducting well-designed RCTs to generate evidence on CIPN symptom management. Additional RCTs are warranted to accelerate the potential use of CNS drugs for CIPN in cancerpatients.
Authors: J P Durand; G Deplanque; V Montheil; J M Gornet; F Scotte; O Mir; A Cessot; R Coriat; E Raymond; E Mitry; P Herait; Y Yataghene; F Goldwasser Journal: Ann Oncol Date: 2011-03-22 Impact factor: 32.976
Authors: Janet M Schloss; Maree Colosimo; Caroline Airey; Paul P Masci; Anthony W Linnane; Luis Vitetta Journal: Clin Nutr Date: 2013-04-13 Impact factor: 7.324
Authors: A A Argyriou; E Chroni; P Polychronopoulos; G Iconomou; A Koutras; T Makatsoris; M K Gerolymos; P Gourzis; K Assimakopoulos; H P Kalofonos Journal: Neurology Date: 2006-12-26 Impact factor: 9.910
Authors: Stefan von Delius; Florian Eckel; Stefan Wagenpfeil; Martina Mayr; Konrad Stock; Frank Kullmann; Florian Obermeier; Johannes Erdmann; Renate Schmelz; Stefan Quasthoff; Helmuth Adelsberger; Rainer Bredenkamp; Roland M Schmid; Christian Lersch Journal: Invest New Drugs Date: 2006-09-13 Impact factor: 3.850
Authors: Robert H Dworkin; Alec B O'Connor; Joseph Audette; Ralf Baron; Geoffrey K Gourlay; Maija L Haanpää; Joel L Kent; Elliot J Krane; Alyssa A Lebel; Robert M Levy; Sean C Mackey; John Mayer; Christine Miaskowski; Srinivasa N Raja; Andrew S C Rice; Kenneth E Schmader; Brett Stacey; Steven Stanos; Rolf-Detlef Treede; Dennis C Turk; Gary A Walco; Christopher D Wells Journal: Mayo Clin Proc Date: 2010-03 Impact factor: 7.616
Authors: Debra L Barton; Edward J Wos; Rui Qin; Bassam I Mattar; Nathan Benjamin Green; Keith S Lanier; James Dewitt Bearden; John W Kugler; Kay L Hoff; Pavan S Reddy; Kendrith M Rowland; Mike Riepl; Bradley Christensen; Charles L Loprinzi Journal: Support Care Cancer Date: 2010-05-25 Impact factor: 3.603
Authors: Ravi D Rao; Patrick J Flynn; Jeff A Sloan; Gilbert Y Wong; Paul Novotny; David B Johnson; Howard M Gross; Samer I Renno; Mohammed Nashawaty; Charles L Loprinzi Journal: Cancer Date: 2008-06-15 Impact factor: 6.860
Authors: Claudia Wing; Masaaki Komatsu; Shannon M Delaney; Matthew Krause; Heather E Wheeler; M Eileen Dolan Journal: Stem Cell Res Date: 2017-06-15 Impact factor: 2.020
Authors: Iwona Filipczak-Bryniarska; Roger M Krzyzewski; Jakub Kucharz; Anna Michalowska-Kaczmarczyk; Justyna Kleja; Jarosław Woron; Katarzyna Strzepek; Lucyna Kazior; Jerzy Wordliczek; Tomasz Grodzicki; Krzysztof Krzemieniecki Journal: Med Oncol Date: 2017-08-17 Impact factor: 3.064
Authors: Rodolfo Daniel Cervantes-Villagrana; Damaris Albores-García; Alberto Rafael Cervantes-Villagrana; Sara Judit García-Acevez Journal: Signal Transduct Target Ther Date: 2020-06-18